Aripiprazole Efficacy and Safety in Schizophrenia Management

Mechanism of Action and Efficacy

Aripiprazole has been shown to improve negative symptoms when used as augmentation therapy (standardized mean difference −0.41, 95% CI −0.79 to −0.03, p = 0.036) 1
Aripiprazole may actually reduce prolactin levels and body weight when used as augmentation therapy 1

Studies show that discontinuation of antipsychotic medication significantly increases the risk of relapse in schizophrenia 2
Switching from antipsychotic polypharmacy to monotherapy is associated with a significant risk of treatment discontinuation (risk ratio 2.28, 95% CI 1.50–3.46) 1
In studies examining the transition from polypharmacy to monotherapy, approximately 20-33% of patients could not tolerate the switch and had to return to combination therapy 1
One study found that participants who switched from polypharmacy to monotherapy experienced greater increases in symptoms in the second half of follow-up and higher rates of discontinuation (42% vs 13%) 1

Lower doses are recommended for elderly patients, those with hepatic impairment, or poor metabolizers of cytochrome P450 2D6 3

While antipsychotic monotherapy is generally recommended as first-line treatment, aripiprazole may be used in combination therapy in specific situations 4
The Finnish Current Care Guideline acknowledges that some patients may benefit from the concurrent use of two antipsychotic medications, particularly when aripiprazole is combined with another antipsychotic to reduce negative symptoms 4
When used in combination therapy, lower doses of each medication may be used to maintain efficacy while reducing side effects 3

Medication discontinuation is a major risk factor for relapse in schizophrenia, with studies showing that 70% of patients require long-term, even lifetime medication to control symptoms 4
Regular monitoring of metabolic parameters is essential, including BMI, waist circumference, blood pressure, HbA1c, glucose, and lipids 5
Lifestyle advice including healthy diet, physical activity promotion, and tobacco cessation should be offered to all patients on antipsychotic medications 5

Aripiprazole has demonstrated efficacy in treating both positive and negative symptoms of schizophrenia, with particular benefit for negative symptoms when used as augmentation therapy (standardized mean difference −0.41, 95% CI −0.79 to −0.03, p = 0.036) 6
When used in combination with other antipsychotics (particularly clozapine), aripiprazole may help reduce side effects such as weight gain, dyslipidemia, hyperprolactinemia, and sexual dysfunction 7

The combination of clozapine with aripiprazole has shown particular promise, with studies indicating this combination may be associated with the lowest risk of psychiatric hospitalization (HR 0.86, 95% CI 0.79–0.94 compared with clozapine monotherapy) 8
When switching from antipsychotic polypharmacy to monotherapy, there is a significant risk of treatment discontinuation (risk ratio 2.28, 95% CI 1.50–3.46), with approximately one-third of patients unable to tolerate the switch 9
Aripiprazole may be beneficial in combination therapy for patients with inadequate response to monotherapy 10

The American Psychiatric Association guidelines endorse monotherapy and do not acknowledge situations where antipsychotic polypharmacy would be recommended as first-line treatment, but allow for augmentation in specific cases 11, 12
NICE guidelines recommend against regular combined antipsychotic medication except for short periods, but allow adding an additional antipsychotic to augment clozapine treatment if clozapine monotherapy proves ineffective 11, 12
The World Federation of Societies of Biological Psychiatry recommends antipsychotic polypharmacy only in treatment-resistant schizophrenia, specifically noting that clozapine combined with another second-generation antipsychotic might have advantages 11, 12

Allow a full 6-8 week trial at therapeutic doses (15-25 mg/day) before concluding treatment failure 11
The Finnish Current Care Guideline specifically states that combining aripiprazole with another antipsychotic may reduce negative symptoms, making this a guideline-endorsed strategy when monotherapy proves insufficient 12